Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 428 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Acute Kidney Insufficiency Clear all

Conditions: Acute Kidney Injury
Interventions: ANG-3777, Placebo; Drug
Lead sponsor: Angion Biomedica Corp; Industry
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 23
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 18 more

Conditions: End-stage Renal Failure, Kidney Graft Rejection
Interventions: Blood drawing for immune monitoring and questionnaires; Other
Lead sponsor: University of Regensburg; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: San Francisco, California • Boston, Massachusetts

Conditions: Hypotension, Acute Kidney Injury
Interventions: Nudge to reduce intraoperative hypotension; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 30,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Los Angeles, California • Santa Monica, California

Conditions: Acute Kidney Injury
Interventions: THR-184, Placebo; Drug
Lead sponsor: Thrasos Innovation, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 31
States / cities: Birmingham, Alabama • Los Angeles, California • Stanford, California + 26 more

Conditions: Kidney Failure, Chronic
Interventions: soy isoflavones; Drug
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2003
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Acute Kidney Injury
Interventions: Suramin, Placebo; Drug
Lead sponsor: Rediscovery Life Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 12
States / cities: Little Rock, Arkansas • La Mesa, California • Los Angeles, California + 9 more

Conditions: Acute Kidney Injury
Interventions: CXA-10, pravastatin, Vytorin® (combination of simvastatin and ezetimibe); Drug
Lead sponsor: Complexa, Inc.; Industry
Eligibility: 19 Years to 30 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Acute Coronary Syndrome, Renal Insufficiency, Ischemia, Myocardial
Interventions: Remote Ischemic Preconditioning; Procedure
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Kidney Failure, Acute, Kidney Failure, Chronic, Blood Platelet Disorders, Hemorrhage
Interventions: measuring Platelet Function Analyser-100 (PFA-100) platelet function before kidney biopsy; Device
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Acute Kidney Injury
Interventions: Selective Cytopheretic Device; Device
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Up to 17 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Birmingham, Alabama • Cincinnati, Ohio

Conditions: Acute Kidney Injury
Interventions: Cardiac Surgery with Cardiopulmonary Bypass; Procedure
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 0 Days to 31 Days
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Acute Kidney Injury, Acute Interstitial Nephritis
Interventions: Infliximab, Prednisone, prednisone (oral); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Cystic Fibrosis (CF), Chronic Kidney Disease(CKD), Acute Kidney Injury
Interventions: Not listed
Lead sponsor: University of Virginia; Other
Eligibility: 7 Years and older
Enrollment: 260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Birmingham, Alabama • Lebanon, New Hampshire • Charlottesville, Virginia

Conditions: COVID-19
Interventions: TXA127, Placebo; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Kidney Injury Following Cardiac Surgery
Interventions: TIN816, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 45 Years to 100 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Phoenix, Arizona • Durham, North Carolina

Conditions: COVID-19, Long COVID
Interventions: MouthLabTM; Device
Lead sponsor: Edith Nourse Rogers Memorial Veterans Hospital; Federal
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Bedford, Massachusetts

Conditions: Drug Use, Alcohol Use, Congestive Heart Failure, Pneumonia, Acute Myocardial Infarction, Diabetes Mellitus, Chronic Obstructive Pulmonary Disease, End-Stage Renal Disease
Interventions: Specialized Community Disease Management, Treatment As Usual; Behavioral
Lead sponsor: Treatment Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Acute Kidney Injury
Interventions: Not listed
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Hypotension
Interventions: Attending real-time decision support, In-room real-time decision support, Attending feedback emails, In-room provider feedback emails, Anesthesia Information Management System (AIMS), Perioperative Data Warehouse (PDW), General anesthesia, Pager system, Central neuraxial anesthesia, Non-cardiac surgery, Propofol, Sevoflurane, Desflurane, Isoflurane, Ephedrine, Phenylephrine, Norepinephrine, Epinephrine, Dobutamine, Dopamine, Isoproterenol, Milrinone, Atropine, Glycopyrrolate, Vasopressin, Terlipressin, Sodium Chloride 0.9%, Ringer's lactate, Hydroxyethyl starch solutions, Fresh Frozen Plasma, Packed Red Blood Cells, Albumin solutions, Plasma-Lyte, Lidocaine, Bupivacaine, Levobupivacaine, Ropivacaine, Mepivacaine, Tetracaine, Prilocaine, Procaine, Chloroprocaine, Benzocaine, Articaine; Procedure · Device · Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 60 Years to 100 Years
Enrollment: 22,435 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Acute Kidney Injury
Interventions: recAP, Placebo; Biological · Other
Lead sponsor: AM-Pharma; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 6
States / cities: Birmingham, Alabama • Tampa, Florida • Idaho Falls, Idaho + 3 more

Conditions: Kidney Tubular Necrosis, Acute
Interventions: Multipotent Stromal Cells, Administration of MSC; Biological
Lead sponsor: AlloCure Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 2
States / cities: Murray, Utah • Salt Lake City, Utah

Conditions: Sepsis, Acute Kidney Injury, Septic Shock
Interventions: Subject management guided by NephroCheck® test, Standard of Care; Device · Other
Lead sponsor: BioMérieux; Industry
Eligibility: 21 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Shreveport, Louisiana • Boston, Massachusetts • New York, New York

Conditions: Acute Kidney Injury, Acute Renal Failure, Heart Failure
Interventions: Dilute unfractionated heparin, Standard concentration unfractionated heparin; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cirrhosis, Liver, End Stage Liver DIsease, Acute Kidney Injury, Liver Transplant; Complications
Interventions: Angiotensin II, Norepinephrine; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Study to Prevent Acute Kidney Injury After Cardiac Surgery Involving Cardiopulmonary Bypass

Reference Group Trial for The ONE Study

A Clinical Decision Support Trial to Reduce Intraoperative Hypotension

A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)

Isoflavones and Acute-phase Response in Chronic Renal Failure

Study of Suramin in Subjects With Furosemide-Resistant AKI

A Study of the PK Interaction of CXA-10 With Pravastatin and Vytorin® in Healthy Males

Remote Ischemic Preconditioning in ACS Patients

Does An Abnormal PFA 100 Predict Bleeding After Renal Biopsy?

A Multi-Center Study of a SCD for Immunomodulatory Dysregulation in Pediatric AKI

Hematologic Ratios in Postoperative Acute Kidney Injury

Infliximab for Immune Checkpoint Inhibitor Associated AKI

Kidney Function in People With Cystic Fibrosis in the Era of HEMT

TXA127 for the Treatment of Severe COVID-19

A Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of TIN816 in Patients at Risk for Acute Kidney Injury Following Cardiac Surgery.

Using Data From a Multisensor Rapid Health Assessment Device to Predict Decompensation in Long COVID (AIDI)

Specialized Community Disease Management to Reduce Substance Use and Hospital Readmissions

Inferior Vena cavaCollapsibility Index in Patients With Acute Kidney Injury

Decision Support for Intraoperative Low Blood Pressure

A Safety, Tolerability, Efficacy and QoL Study of Human recAP in the Treatment of Patients With SA-AKI

Allogeneic Multipotent Stromal Cell Treatment for Acute Kidney Injury Following Cardiac Surgery

A Study Looking at the Use of Biomarkers to Provide Early Indication of Acute Kidney Injury in Patients With Sepsis (Limiting AKI Progression In Sepsis)

A Comparison of Dilute Versus Concentrated Heparin for CRRT Anticoagulation

Angiotensin 2 for AKI After OLT